CLINICAL_TRIALS
trial_result
· 2017-04-07
Clinical Trial Update: Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma [Phase 2]
Summary
Phase II trial evaluating sunitinib rechallenge in metastatic renal cell carcinoma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amsterdam UMC, location VUmc | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED